Maravai LifeSciences Holdings Inc. Class A Common Stock vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while iShares 1 3 Year Treasury Bond ETF trades at $81.31 (market cap $26.87B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 27.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and iShares 1 3 Year Treasury Bond ETF for 64 Days on average.
| MRVI | SHY | |
|---|---|---|
Market Cap | $972.90M | $26.87B |
Volume | 4,325,710 | 3,180,822 |
Sector | Health | Fixed Income |
52-Week High | $9.00 | $83.18 |
52-Week Low | $2.83 | $81.05 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $1.08B | — |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SHY, a US stock, trades at $81.19 with minimal daily movement, reflecting stability amid broader bond market volatility. Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend actions provide income, but key financial ratios are unavailable. The stock's price action is tightly range-bound with support and resistance near $81.
The outlook for SHY is cautious due to bearish technical signals and a lack of fundamental data. Risks include interest rate sensitivity and macroeconomic pressures from rising bond yields. Investment opportunities may lie in its dividend yield if fundamentals strengthen, but current sentiment and technicals suggest limited near-term upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →